SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+15.9%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$840M
AUM Growth
+$840M
(-5%)
Cap. Flow
-$178M
Cap. Flow
% of AUM
-21.2%
Top 10 Holdings %
Top 10 Hldgs %
99.97%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Alkermes
ALKS
|
$133M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$23.2M |
| 3 |
Gilead Sciences
GILD
|
$17.5M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$4.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $234M | 27.88% | 8,964,640 -5,075,360 | -36% | -$133M |
|
2
Ironwood Pharmaceuticals
IRWD
$214M
| $203M | 24.17% | 16,390,000 | – | – |
|
3
Biogen
BIIB
$19.4B
| $178M | 21.19% | 643,000 | – | – |
|
|
4
Gilead Sciences
GILD
$140B
| $91.8M | 10.92% | 1,068,750 -204,350 | -16% | -$17.5M |
|
5
Innoviva
INVA
$1.29B
| $87.6M | 10.43% | 6,614,000 | – | – |
|
6
Mersana Therapeutics
MRSN
$36.5M
| $23.4M | 2.79% | 3,997,010 | – | – |
|
|
7
BioCryst Pharmaceuticals
BCRX
$1.74B
| $11.3M | 1.34% | 980,288 -410,502 | -30% | -$4.71M |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $5.82M | 0.69% | 4,807,000 -19,191,000 | -80% | -$23.2M |
|
9
Vor Biopharma
VOR
$250M
| $4.11M | 0.49% | 618,000 | – | – |
|
|
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $590K | 0.07% | 500,356 | – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $254K | 0.03% | 185,183 | – | – |
|